rs766449694
Variant summary
Our verdict is Benign. The variant received -10 ACMG points: 0P and 10B. BP7BA1BP4
This summary comes from the ClinGen Evidence Repository: The variant NM_001005361.3:c.162-6del in DNM2 is an intronic deletion variant. The highest population filtering allele frequency in gnomAD v4.1 is 0.0001715 (15/60000 alleles) in the Admixed American population, which is higher than the ClinGen Congenital Myopathies VCEP threshold (≥0.0000015) for BA1, and therefore meets this criterion (BA1). The c.162-6del variant is an intronic variant that is not predicted by SpliceAI to impact splicing. In addition, it occurs at a nucleotide that is not conserved as shown by UCSC Genome Browser (BP4, BP7). In summary, this variant meets the criteria to be classified as benign for autosomal dominant centronuclear myopathy based on the ACMG/AMP criteria applied, as specified by theClinGen Congenital Myopathies VCEP: BA1, BP4, BP7. (ClinGen Congenital Myopathies VCEP specifications version 1; 8/7/2024) LINK:https://erepo.genome.network/evrepo/ui/classification/CA9200718/MONDO:0018947/148
Frequency
Consequence
NM_001005361.3 splice_region, intron
Scores
Clinical Significance
Conservation
Publications
- autosomal dominant centronuclear myopathyInheritance: AD Classification: DEFINITIVE, STRONG, MODERATE, SUPPORTIVE Submitted by: ClinGen, Orphanet, Ambry Genetics, Labcorp Genetics (formerly Invitae)
- Charcot-Marie-Tooth diseaseInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- Charcot-Marie-Tooth disease dominant intermediate BInheritance: AD Classification: STRONG, MODERATE, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, Orphanet
- autosomal dominant Charcot-Marie-Tooth disease type 2MInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- fetal akinesia-cerebral and retinal hemorrhage syndromeInheritance: AR Classification: SUPPORTIVE, LIMITED Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), Orphanet
- hereditary spastic paraplegiaInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
Genome browser will be placed here
ACMG classification
Our verdict: Benign. The variant received -10 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152188Hom.: 0 Cov.: 31 show subpopulations
GnomAD2 exomes AF: 0.0000557 AC: 14AN: 251494 AF XY: 0.0000147 show subpopulations
GnomAD4 exome AF: 0.0000137 AC: 20AN: 1461866Hom.: 0 Cov.: 31 AF XY: 0.00000688 AC XY: 5AN XY: 727232 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152188Hom.: 0 Cov.: 31 AF XY: 0.0000269 AC XY: 2AN XY: 74354 show subpopulations ⚠️ The allele balance in gnomAD version 4 Genomes is significantly skewed from the expected value of 0.5.
ClinVar
Submissions by phenotype
not specified Benign:1
This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -
Charcot-Marie-Tooth disease dominant intermediate B Benign:1
- -
Centronuclear myopathy Benign:1
The variant NM_001005361.3:c.162-6del in DNM2 is an intronic deletion variant. The highest population filtering allele frequency in gnomAD v4.1 is 0.0001715 (15/60000 alleles) in the Admixed American population, which is higher than the ClinGen Congenital Myopathies VCEP threshold (≥0.0000015) for BA1, and therefore meets this criterion (BA1). The c.162-6del variant is an intronic variant that is not predicted by SpliceAI to impact splicing. In addition, it occurs at a nucleotide that is not conserved as shown by UCSC Genome Browser (BP4, BP7). In summary, this variant meets the criteria to be classified as benign for autosomal dominant centronuclear myopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen Congenital Myopathies VCEP: BA1, BP4, BP7. (ClinGen Congenital Myopathies VCEP specifications version 1; 8/7/2024) -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at